Long-term results of allogeneic hematopoietic stem cell
transplantation after reduced-intensity conditioning with
busulfan, fludarabine, and antithymocyte globulin

J 2011

Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin

KREJČÍ, Marta, Yvona BRYCHTOVÁ, Michael DOUBEK, Miroslav TOMIŠKA, Milan NAVRÁTIL et. al.

Základní údaje

Originální název

Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin

Autoři

KREJČÍ, Marta (203 Česká republika, garant, domácí), Yvona BRYCHTOVÁ (203 Česká republika), Michael DOUBEK (203 Česká republika, domácí), Miroslav TOMIŠKA (203 Česká republika, domácí), Milan NAVRÁTIL (203 Česká republika, domácí), Zdeněk RÁČIL (203 Česká republika, domácí), Dana DVOŘÁKOVÁ (203 Česká republika, domácí), Ondřej HORKÝ (203 Česká republika, domácí), Martina LENGEROVÁ (203 Česká republika, domácí), Šárka POSPÍŠILOVÁ (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Neoplasma, 2011, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.440

Kód RIV

RIV/00216224:14110/11:00054666

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2011_05_406

UT WoS

000295309700007

Klíčová slova anglicky

reduced-intensity conditioning; fludarabine; busulfan; antithymocyte globulin

Příznaky

Mezinárodní význam

Změněno: 3. 1. 2012 08:36, Mgr. Michal Petr

Anotace

V originále

Reduced-intensity conditioning (RIG) is widely used for allogeneic stem cell transplantation (SCT). Here we present our long-term experience with RIG regimen consisting of fludarabine (30 mg/m(2)/day on days -10 to -5), busulfan (4mg/kg/day on days -6 and -5) and antithymocyte globulin (ATG Fresenius, 10 mg/kg/day on days -4 to -1) (Flu-Bu-ATG) in a cohort of 71 patients with various hematological malignancies including chronic myeloid leukemia (24 patients), acute myeloid leukemia (19 patients), lymphoma (20 patients), multiple myeloma (3 patients), myelodysplastic syndrome (3 patients), and myelofibrosis (2 patients). The median age was 50 years. The overall response rate was 87%, including 83% CR and 4% PR. The incidence of acute and chronic GVHD was 35% and 52% and the cumulative incidence of non-relapse mortality at 1 year and 4 years was 8% and 14%. With the median follow-up of 55.0 months, the 2- and 4-year event-free survival (EFS) was 49.0% and 40.3%, and the overall survival (OS) was 73.2% and 62.6%, respectively. Gender, age at SCT, type of donor, disease status at SCT, previous autologous transplantation, and complete chimerism by day +100 did not significantly influence EFS and OS. In a multivariate analysis, no presence of chronic GVHD (p=0.029, HR: 2.5),and diagnosis other than CML (p=0.018, HR: 4.6), and CD34+ dose < 5x10(6)/kg (p=0.010, HR: 2.8) were significant predictors of poor OS. Flu-Bu-ATG protocol is a RIG regimen that combines effective disease control with low non-relapse mortality and acceptable toxicity profile.

Návaznosti

MSM0021622430, záměr

Název: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Citovat

KREJČÍ, Marta, Yvona BRYCHTOVÁ, Michael DOUBEK, Miroslav TOMIŠKA, Milan NAVRÁTIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Ondřej HORKÝ, Martina LENGEROVÁ, Šárka POSPÍŠILOVÁ a Jiří MAYER. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Neoplasma. 2011, roč. 58, č. 5, s. 406-414. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2011_05_406.

@article{964453,
   author = {Krejčí, Marta and Brychtová, Yvona and Doubek, Michael and Tomiška, Miroslav and Navrátil, Milan and Ráčil, Zdeněk and Dvořáková, Dana and Horký, Ondřej and Lengerová, Martina and Pospíšilová, Šárka and Mayer, Jiří},
   article_number = {5},
   doi = {http://dx.doi.org/10.4149/neo_2011_05_406},
   keywords = {reduced-intensity conditioning; fludarabine; busulfan; antithymocyte globulin},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin},
   volume = {58},
   year = {2011}
}

TY  - JOUR
ID  - 964453
AU  - Krejčí, Marta - Brychtová, Yvona - Doubek, Michael - Tomiška, Miroslav - Navrátil, Milan - Ráčil, Zdeněk - Dvořáková, Dana - Horký, Ondřej - Lengerová, Martina - Pospíšilová, Šárka - Mayer, Jiří
PY  - 2011
TI  - Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin
JF  - Neoplasma
VL  - 58
IS  - 5
SP  - 406-414
EP  - 406-414
SN  - 00282685
KW  - reduced-intensity conditioning
KW  - fludarabine
KW  - busulfan
KW  - antithymocyte globulin
N2  - Reduced-intensity conditioning (RIG) is widely used for allogeneic stem cell transplantation (SCT). Here we present our long-term experience with RIG regimen consisting of fludarabine (30 mg/m(2)/day on days -10 to -5), busulfan (4mg/kg/day on days -6 and -5) and antithymocyte globulin (ATG Fresenius, 10 mg/kg/day on days -4 to -1) (Flu-Bu-ATG) in a cohort of 71 patients with various hematological malignancies including chronic myeloid leukemia (24 patients), acute myeloid leukemia (19 patients), lymphoma (20 patients), multiple myeloma (3 patients), myelodysplastic syndrome (3 patients), and myelofibrosis (2 patients). The median age was 50 years. The overall response rate was 87%, including 83% CR and 4% PR. The incidence of acute and chronic GVHD was 35% and 52% and the cumulative incidence of non-relapse mortality at 1 year and 4 years was 8% and 14%. With the median follow-up of 55.0 months, the 2- and 4-year event-free survival (EFS) was 49.0% and 40.3%, and the overall survival (OS) was 73.2% and 62.6%, respectively. Gender, age at SCT, type of donor, disease status at SCT, previous autologous transplantation, and complete chimerism by day +100 did not significantly influence EFS and OS. In a multivariate analysis, no presence of chronic GVHD (p=0.029, HR: 2.5),and diagnosis other than CML (p=0.018, HR: 4.6), and CD34+ dose < 5x10(6)/kg (p=0.010, HR: 2.8) were significant predictors of poor OS. Flu-Bu-ATG protocol is a RIG regimen that combines effective disease control with low non-relapse mortality and acceptable toxicity profile.
ER  -

KREJČÍ, Marta, Yvona BRYCHTOVÁ, Michael DOUBEK, Miroslav TOMIŠKA, Milan NAVRÁTIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Ondřej HORKÝ, Martina LENGEROVÁ, Šárka POSPÍŠILOVÁ a Jiří MAYER. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. \textit{Neoplasma}. 2011, roč.~58, č.~5, s.~406-414. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2011\_{}05\_{}406.

Přehled o publikaci